Research progress on substitution of in vivo method(s) by in vitro method(s) for human vaccine potency assays

References

• Vaccines Licensed for Use in the United States [Internet]. Washington D.C: FDA [2022 November 30] Available from: https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states
   Google Scholar
• ChPC. Pharmacopoeia of the People’s Republic of China (VolIII). Beijing: China Medical Science Press; 2020.
   Google Scholar
• EDQM. . European Pharmacopoeia. 10.0th ed. Strasbourgh France: European Department for the Quality of Medicines. 2019.
   Google Scholar
• WHO. WHO guidelines on nonclinical evaluation of vaccines. 2005.
   Google Scholar
• Ranheim T, Mozier N, Egan W. Vaccine analysis: strategies, principles, and control. Berlin Heidelberg: Springer. Chapter 13, Vaccine Potency Assays. 2015; 521–541.
   Google Scholar
• EMA. Validation of analytical procedures Q2 (R2). 2022.
   Google Scholar
• Verch T, Trausch JJ, Shank-Retzlaff M. Principles of vaccine potency assays. Bioanalysis. 2018 Feb;10(3):163–180.
   PubMed Web of Science ®Google Scholar
• WHO. Evaluation of the quality, safety and efficacy of messenger RNA vaccines for the prevention of infectious diseases: regulatory considerations. 2021.
   Google Scholar
• WHO. Guidelines on the quality, safety and efficacy of plasmid DNA vaccines. 2021.
   Google Scholar
• Sanyal G. Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies. NPJ Vaccines. 2022 May 5;7(1):50.
   PubMed Web of Science ®Google Scholar
• Metz B, Hendriksen CF, Jiskoot W, et al. Reduction of animal use in human vaccine quality control: opportunities and problems. Vaccine. 2002 Jun 7;20(19–20):2411–2430.
   PubMed Web of Science ®Google Scholar
• Stalpers CAL, Retmana IA, Pennings JLA, et al. Variability of in vivo potency tests of Diphtheria, Tetanus and acellular Pertussis (DTaP) vaccines. Vaccine. 2021 Apr 28;39(18):2506–2516.
   PubMed Web of Science ®Google Scholar
• Commission E. Summary Report on the statistics on the use of animals for scientific purposes in the member States of the European Union and Norway in 2018. 2021.
   Google Scholar
• Poston R, Hill R, Allen C, et al. Achieving scientific and regulatory success in implementing non-animal approaches to human and veterinary rabies vaccine testing: a NICEATM and IABS workshop report. Biologicals. 2019 Jul;60:8–14.
   PubMed Web of Science ®Google Scholar
• McFarland R, Verthelyi D, Casey W, et al. Non-animal replacement methods for human vaccine potency testing: state of the science and future directions. Procedia Vaccinol. 2011;5:16–32.
   PubMedGoogle Scholar
• Lilley E, Isbrucker R, Ragan I, et al. Integrating 3Rs approaches in WHO guidelines for the batch release testing of biologicals. Biologicals. 2021 Nov;74:24–27.
   PubMed Web of Science ®Google Scholar
• Milne C, Buchheit KH. EDQM’s 3R activities in the field of quality control of vaccines. 2012.
   Google Scholar
• Akkermans A, Chapsal JM, Coccia EM, et al. Animal testing for vaccines. Implementing replacement, reduction and refinement: challenges and priorities. Biologicals. 2020 Nov;68:92–107.
   PubMed Web of Science ®Google Scholar
• EDQM General text: substitution of in vivo methods by in vitro methods for the quality control of vaccines European Pharmacopoeia 10.0th ed.Strasbourgh France: European Department for the Quality of Medicines. 2019.
   Google Scholar
• EDQM. Biological assays: assay of hepatitis B vaccine(rDNA) European Pharmacopoeia 10.0th ed.Strasbourgh France: European Department for the Quality of Medicines. 2019.
   Google Scholar
• Cuervo ML. de Castro Yanes AF. Comparison between in vitro potency tests for Cuban hepatitis B vaccine: contribution to the standardization process. Biologicals. 2004 Dec;32(4):171–176.
   PubMed Web of Science ®Google Scholar
• ML C, AL S, IA N, et al. Validation of a new alternative for determining in vitro potency in vaccines containing Hepatitis B from two different manufacturers. Biologicals. 2008 Nov;36(6):375–382.
   PubMed Web of Science ®Google Scholar
• Descamps J, Giffroy D, Remy E, et al. A case study of development, validation, and acceptance of a non-animal method for assessing human vaccine potency. Procedia in Vaccinol. 2011;5:184–191.
   Google Scholar
• EDQM. Biological assay: assay of hepatitis A vaccine . European Pharmacopoeia. 10th ed. Strasbourgh France: European Department for the Quality of Medicines. 2019.
   Google Scholar
• EDQM. General monograph: poliomyelitis Vaccine (Inactivated). European Pharmacopoeia. 10th ed. Strasbourgh France: European Department for the Quality of Medicines.2019.
   Google Scholar
• EDQM. General monograph: human papillomavirus vaccine (rDNA). European Pharmacopoeia. 10th ed. Strasbourgh France: European Department for the Quality of Medicines. 2019.
   Google Scholar
• Jallet C, Tordo N. In Vitro ELISA test to evaluate rabies vaccine potency. J Vis Exp. 2020 May;11:159.
   Google Scholar
• Morgeaux S, Poirier B, Ragan CI, et al. Replacement of in vivo human rabies vaccine potency testing by in vitro glycoprotein quantification using ELISA - Results of an international collaborative study. Vaccine. 2017 Feb 7;35(6):966–971.
   PubMed Web of Science ®Google Scholar
• Ye K, Shi D, Zhang Z, et al. A chemiluminescence immunoassay for precise automatic quality control of glycoprotein in human rabies vaccine. Vaccine. 2021 Dec 17;39(51):7470–7476.
   PubMed Web of Science ®Google Scholar
• Coombes L, Tierney R, Rigsby P, et al. In vitro antigen ELISA for quality control of tetanus vaccines. Biologicals. 2012 Nov;40(6):466–472.
   PubMed Web of Science ®Google Scholar
• Riches-Duit R, Hassall L, Kogelman A, et al. Characterisation of tetanus monoclonal antibodies as a first step towards the development of an in vitro vaccine potency immunoassay. Biologicals. 2021 Jun;71:31–41.
   PubMed Web of Science ®Google Scholar
• Kim DK, Kim HY, Kim JY, et al. Development of an in vitro antigen-detection test as an alternative method to the in vivo plaque reduction neutralization test for the quality control of Japanese encephalitis virus vaccine. Microbiol Immunol. 2012 Jul;56(7):463–471.
   PubMed Web of Science ®Google Scholar
• EDQM. General monograph: assay of pertussis vaccine (whole cell). European Pharmacopoeia. 10.0th ed. Strasbourgh France: European Department for the Quality of Medicines. 2019.
   Google Scholar
• EDQM. General monograph: tick-borne encephalitis vaccine (inactivated) European Pharmacopoeia. 10.0th ed. Strasbourgh France: European Department for the Quality of Medicines. 2019.
   Google Scholar
• EDQM. General monograph: rabies vaccine for human use prepared in cell cultures. European Pharmacopoeia. 10.0th ed. Strasbourgh France: European Department for the Quality of Medicines. 2019.
   Google Scholar
• Kirnbauer R, Booy F, Cheng N, et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):12180–12184.
   PubMed Web of Science ®Google Scholar
• Waters JA, Brown SE, Steward MW, et al. Analysis of the antigenic epitopes of hepatitis B surface antigen involved in the induction of a protective antibody response. Virus Res. 1992 Jan;22(1):1–12.
   PubMed Web of Science ®Google Scholar
• Wood DJ, Heath AB, Kersten GF, et al. A new WHO international reference reagent for use in potency assays of inactivated poliomyelitis vaccine. Biologicals. 1997 Mar;25(1):59–64.
   PubMed Web of Science ®Google Scholar
• Liu CC, Chou AH, Lien SP, et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine. 2011 Jun 10;29(26):4362–4372.
   PubMed Web of Science ®Google Scholar
• Weintraub A. Immunology of bacterial polysaccharide antigens. Carbohydr Res. 2003 Nov 14;338(23):2539–2547.
   PubMed Web of Science ®Google Scholar
• Dagan R, Givon-Lavi N, Fraser D, et al. Serum serotype-specific pneumococcal anticapsular immunoglobulin g concentrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J Infect Dis. 2005 Aug 1;192(3):367–376.
   PubMed Web of Science ®Google Scholar
• EDQM. General monograph: typhoid polysaccharide vaccine European Pharmacopoeia. 10.0th ed. Strasbourgh France: European Department for the Quality of Medicines. 2019.
   Google Scholar
• EDQM. General monograph: pneumococcal polysaccharide vaccine European Pharmacopoeia. 10.0th ed. Strasbourgh France: European Department for the Quality of Medicines. 2019.
   Google Scholar
• EDQM. General monograph: meningococcal polysaccharide vaccine European Pharmacopoeia. 10.0th ed. Strasbourgh France: European Department for the Quality of Medicines. 2019.
   Google Scholar
• Stokes W, McFarland R, Kulpa-Eddy J, et al. Report on the international workshop on alternative methods for human and veterinary rabies vaccine testing: state of the science and planning the way forward. Biologicals. 2012;40(5):369–381.
   PubMed Web of Science ®Google Scholar
• Stirling C. Consistency as tool to support in vitro batch potency testing in GMP production. Develop in Bio. 2012;134:115–118.
   Google Scholar
• Bruysters MWP, Schiffelers M-J, Hoonakker M, et al. Drivers and barriers in the consistency approach for vaccine batch release testing: report of an international workshop. Biologicals. 2017;48:1–5.
   PubMed Web of Science ®Google Scholar
• Russell WMS BR. The principles of humane experimental technique. London: Methuen. 1959. Reprinted 1992.
   Google Scholar
• Smyth DH Alternatives to Animal Experiments. 1978.
   Google Scholar
• ECBS. Guideline for Independent Lot Release of vaccines by Regulatory Anthorities. 2010.
   Google Scholar
• CoE. European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes (European Treaty Series - No. Vol. 123. Strasbourg: Council of Europe; 1986.
   Google Scholar
• MHRA. Substitution of in vivo method method(s) for the quality control of vaccines. 2019.
   Google Scholar
• IPC releases draft general chapter on substitution of in-vivo method by in-vitro method for quality control of vaccine. [Internet]. Mumbai India; [2022 November 30]. Available from: http://www.pharmabiz.com/NewsDetails.aspx?aid=153900&sid=1
   Google Scholar
• Shanmugham R, Thirumeni N, Rao VS, et al. Immunocapture enzyme-linked immunosorbent assay for assessment of in vitro potency of recombinant hepatitis B vaccines. Clin Vaccine Immunol. 2010 Aug;17(8):1252–1260.
   PubMedGoogle Scholar
• WHO. Recommendations to assure the quality, safety and efficacy of recombinant Hepatitis B Vaccines. 2013.
   Google Scholar
• Poirier B, Variot P, Delourme P, et al. Would an in vitro ELISA test be a suitable alternative potency method to the in vivo immunogenicity assay commonly used in the context of international Hepatitis A vaccines batch release? Vaccine. 2010 Feb 17;28(7):1796–1802.
   PubMed Web of Science ®Google Scholar
• Wilton T. Methods for the quality control of inactivated poliovirus vaccines. Methods Mol Biol. 2016;1387:279–297.
   PubMedGoogle Scholar
• Duchene M. Production, testing and perspectives of IPV and IPV combination vaccines: GSK biologicals’ view. Biologicals. 2006 Jun;34(2):163–166.
   PubMed Web of Science ®Google Scholar
• EDQM. In vivo assay of poliomyelitis vaccine (inactivated): guideline on waiving of the in vivo assay of the poliomyelitis vaccine (inactivated) and its combinations. European Pharmacopoeia. 5.6th ed. Strasbourgh France: European Department for the Quality of Medicines. 2007.
   Google Scholar
• Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol. 1993 Jan;67(1):315–322.
   PubMed Web of Science ®Google Scholar
• Shank-Retzlaff M, Wang F, Morley T, et al. Correlation between mouse potency and in vitro relative potency for human papillomavirus Type 16 virus-like particles and Gardasil vaccine samples. Hum Vaccin. 2005 Sep-Oct;1(5):191–197.
   PubMed Web of Science ®Google Scholar
• WHO. Recommendations to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines. 2016.
   Google Scholar
• Barth R, Diderrich G, Weinmann E. NIH test, a problematic method for testing potency of inactivated rabies vaccine. Vaccine. 1988 Aug;6(4):369–377.
   PubMed Web of Science ®Google Scholar
• Schiffelers MJ, Blaauboer B, Bakker W, et al. Replacing the NIH test for rabies vaccine potency testing: a synopsis of drivers and barriers. Biologicals. 2014 Jul;42(4):205–217.
   PubMed Web of Science ®Google Scholar
• Servat A, Kempff S, Brogat V, et al. A step forward in the quality control testing of inactivated rabies vaccines - extensive evaluation of European vaccines by using alternative methods to the in vivo potency tests. Altern Lab Anim. 2015 Mar;43(1):19–27.
   PubMed Web of Science ®Google Scholar
• Asgary V, Mojtabavi N, Janani A, et al. Development of a time and cost benefit antibody binding test-based method for determination of rabies vaccine potency. Viral Immunol. 2017 Apr;30(3):204–209.
   PubMed Web of Science ®Google Scholar
• Oei HL, Krauss H. [Potency testing of inactivated rabies vaccines with the antibody binding test in comparison with the NIH and habel test(author’s transl)]. Zentralbl Bakteriol Orig A. 1975;231(1–3):1–14.
   PubMedGoogle Scholar
• Fitzgerald EA, Needy CF. Use of the single radial immunodiffusion test as a replacement for the NIH mouse potency test for rabies vaccine. Dev Biol Stand. 1986;64:73–79.
   PubMedGoogle Scholar
• Ferguson M, Schild GC. A single-radial-immunodiffusion technique for the assay of rabies glycoprotein antigen: application for potency tests of vaccines against rabies. J Gen Virol. 1982 Mar;59(Pt 1):197–201.
   PubMedGoogle Scholar
• Vogel I, Kundi M, Gerstl F. A modification of the single radial immunodiffusion potency test (SRD) for rabies vaccines. J Biol Stand. 1989 Jan;17(1):75–83.
   PubMedGoogle Scholar
• Fournier-Caruana J, Poirier B, Haond G, et al. Inactivated rabies vaccine control and release: use of an ELISA method. Biologicals. 2003 Mar;31(1):9–16.
   PubMed Web of Science ®Google Scholar
• Aavula SM, Abhinay G, Nimmagadda SV, et al. A novel in vitro ELISA for estimation of glycoprotein content in human rabies vaccines. J Immunoassay Immunochem. 2017;38(4):400–410.
   PubMedGoogle Scholar
• Lyng J, Bentzon MW, Ferguson M, et al. Rabies vaccine standardization: international collaborative study for the characterization of the fifth international standard for rabies vaccine. Biologicals. 1992 Dec;20(4):301–313.
   PubMed Web of Science ®Google Scholar
• Chabaud-Riou M, Moreno N, Guinchard F, et al. G-protein based ELISA as a potency test for rabies vaccines. Biologicals. 2017 Mar;46:124–129.
   PubMed Web of Science ®Google Scholar
• Toinon A, Moreno N, Chausse H, et al. Potency test to discriminate between differentially over-inactivated rabies vaccines: agreement between the NIH assay and a G-protein based ELISA. Biologicals. 2019 Jul;60:49–54.
   PubMed Web of Science ®Google Scholar
• Gibert R, Alberti M, Poirier B, et al. A relevant in vitro ELISA test in alternative to the in vivo NIH test for human rabies vaccine batch release. Vaccine. 2013 Dec 5;31(50):6022–6029.
   PubMed Web of Science ®Google Scholar
• WHO. Recommendations for Japanese encephalitis vaccine (inactivated) for human use. 2010.
   Google Scholar
• Kim BC, Kim DK, Kim HJ, et al. A collaborative study of an alternative in vitro potency assay for the Japanese encephalitis vaccine. Virus Res. 2016 Sep;2(223):190–196.
   Google Scholar
• WHO. Recommendations to assure the quality, safety and efficacy of enterovirus 71 vaccines (inactivated). 2020.
   Google Scholar
• Bruckner L, Cussler K, Halder M, et al. Three Rs approaches in the quality control of inactivated rabies vaccines. The report and recommendations of ECVAM workshop 48. Altern Lab Anim. 2003 Sep;31(4):429–454.
   PubMed Web of Science ®Google Scholar
• Josefsberg JO, Buckland B. Vaccine process technology. Biotechnol Bioeng. 2012 Jun;109(6):1443–1460.
   PubMed Web of Science ®Google Scholar
• van de Berg D, Kis Z, Behmer CF, et al. Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases. NPJ Vaccines. 2021 Apr 29;6(1):65.
   PubMed Web of Science ®Google Scholar
• van den Biggelaar R, Hoefnagel MHN, Vandebriel RJ, et al. Overcoming scientific barriers in the transition from in vivo to non-animal batch testing of human and veterinary vaccines. Expert Rev Vaccines. 2021 Oct;20(10):1221–1233.
   PubMed Web of Science ®Google Scholar
• EMA. VICH GL2 Validation of analytical procedures: methodology. 1998.
   Google Scholar
• Ranheim T, Mathis PK, Joelsson DB, et al. Development and application of a quantitative RT-PCR potency assay for a pentavalent rotavirus vaccine (RotaTeq). J Virol Methods. 2006 Feb;131(2):193–201.
   PubMed Web of Science ®Google Scholar
• Charlton B, Hockley J, Laassri M, et al. The use of next-generation sequencing for the quality control of live-attenuated polio vaccines. J Infect Dis. 2020 Nov 9;222(11):1920–1927.
   PubMed Web of Science ®Google Scholar
• Ugozzoli M, Laera D, Nuti S, et al. Flow cytometry: an alternative method for direct quantification of antigens adsorbed to aluminum hydroxide adjuvant. Anal Biochem. 2011 Nov 15;418(2):224–230.
   PubMed Web of Science ®Google Scholar
• Byrne-Nash RT, Miller DF, Bueter KM, et al. VaxArray potency assay for rapid assessment of “pandemic” influenza vaccines. NPJ Vaccines. 2018;3(1):43.
   PubMed Web of Science ®Google Scholar
• Wang F, Puddy AC, Mathis BC, et al. Using QPCR to assign infectious potencies to adenovirus based vaccines and vectors for gene therapy: toward a universal method for the facile quantitation of virus and vector potency. Vaccine. 2005 Aug 22;23(36):4500–4508.
   PubMed Web of Science ®Google Scholar
• Lourenç Correia Moreira B, Aparecida Pereira L, Lappas Gimenez AP, et al. Development and validation of a real-time RT-PCR assay for the quantification of rabies virus as quality control of inactivated rabies vaccines. J Virol Methods. 2019;270:46–51.
   PubMed Web of Science ®Google Scholar